AbbVie (ABBV) Amortizatization of Intangibles (2012 - 2026)

AbbVie (ABBV) reported Amortizatization of Intangibles of $1.7 billion for Q1 2026, down 8.5% year-over-year from $1.9 billion in Q1 2025, and down 4.33% quarter-over-quarter from $1.8 billion in Q4 2025.

AbbVie (ABBV) Amortizatization of Intangibles (2012 - 2026) Analysis & Trends

AbbVie (ABBV) has 15 years of Amortizatization of Intangibles data on file, last reported at $1.7 billion in Q1 2026.

  • Amortizatization of Intangibles for Q1 2026 came in at $1.7 billion, down 8.5% year-over-year; the trailing twelve-month figure through Mar 2026 was $7.3 billion (down 3.39% YoY), and the FY2025 annual result was $7.4 billion, down 2.93% from the prior year.
  • Amortizatization of Intangibles retreated to $1.7 billion in Q1 2026 per ABBV's latest filing, from $1.8 billion in the prior quarter.
  • Over five years, Amortizatization of Intangibles peaked at $2.1 billion in Q2 2023 and troughed at $1.7 billion in Q1 2026.
  • A 5-year average of $1.9 billion and a median of $1.9 billion in 2024 frame the typical range for Amortizatization of Intangibles.
  • The sharpest annual moves came in 2022 and 2023: Amortizatization of Intangibles slipped 10.0% in 2022, then rose 16.67% in 2023.
  • A 5-year view of Amortizatization of Intangibles shows it stood at $2.0 billion in 2022, then decreased by 7.85% to $1.8 billion in 2023, then increased by 1.68% to $1.9 billion in 2024, then dropped by 5.18% to $1.8 billion in 2025, then dropped by 4.33% to $1.7 billion in 2026.
  • Business Quant data shows ABBV's Amortizatization of Intangibles at $1.7 billion in Q1 2026, $1.8 billion in Q4 2025, and $1.9 billion in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Amortizatization of Intangibles (Qtr)
1 Gsk 92,316,836.42 Bn 92,316,831.46 Bn 7.76 Bn -
2 Eli Lilly 983.57 Bn 978.29 Bn 16.22 Bn -
3 Johnson & Johnson 553.56 Bn 531.50 Bn 15.96 Bn -
4 AbbVie 383.35 Bn 374.00 Bn 10.78 Bn 1.70 Bn
5 Merck 281.71 Bn 276.06 Bn 12.09 Bn 931.00 Mn
6 Amgen 182.20 Bn 170.16 Bn 5.87 Bn -
7 Gilead Sciences 153.71 Bn 145.98 Bn 5.52 Bn 596.00 Mn
8 Pfizer 143.75 Bn 130.98 Bn -1.21 Bn -
9 Bristol Myers Squibb 109.71 Bn 99.25 Bn 8.07 Bn -
10 Novartis Ag 108.28 Bn 107.60 Bn - -

Historic Data

Download Data
DateValue
Mar 31, 2026 1.70 Bn
Mar 31, 2026 1.70 Bn
Dec 31, 2025 1.78 Bn
Dec 31, 2025 1.78 Bn
Sep 30, 2025 1.90 Bn
Sep 30, 2025 1.90 Bn
Jun 30, 2025 1.90 Bn
Jun 30, 2025 1.90 Bn
Mar 31, 2025 1.86 Bn
Mar 31, 2025 1.86 Bn
Dec 31, 2024 1.87 Bn
Dec 31, 2024 1.87 Bn
Sep 30, 2024 1.90 Bn
Sep 30, 2024 1.90 Bn
Jun 30, 2024 1.90 Bn
Jun 30, 2024 1.90 Bn
Mar 31, 2024 1.90 Bn
Mar 31, 2024 1.90 Bn
Dec 31, 2023 1.84 Bn
Dec 31, 2023 1.84 Bn